Research programme: beta-elemene nano-emulsion formulation - ADVENTRX Pharmaceuticals

Drug Profile

Research programme: beta-elemene nano-emulsion formulation - ADVENTRX Pharmaceuticals

Alternative Names: ANX 570; Beta-elemene - ADVENTRX Pharmaceuticals; Elemene - ADVENTRX Pharmaceuticals; SDP-111; β-elemene - ADVENTRX Pharmaceuticals

Latest Information Update: 30 Oct 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ADVENTRX Pharmaceuticals
  • Class Antineoplastics; Sesquiterpenes; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jan 2007 ANX 570 is available for licensing (http://www.adventrx.com)
  • 28 Apr 2006 SD Pharmaceuticals has been acquired by ADVENTRX Pharmaceuticals
  • 12 Apr 2006 Preclinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top